The Efficacy of Quinolones and Fluoroquinolones in the Medicine: a review study

Authors

  • Adnan Mahmood Middle Technical University
  • Xin Liu Therapeutics Research Centre, UQ School of Medicine, Translational Research Institute
  • Jeffrey Grice Therapeutics Research Centre, UQ School of Medicine, Translational Research Institute
  • Gregory Medley Therapeutics Research Centre, UQ School of Medicine, Translational Research Institute
  • Michael Roberts School of Pharmacy & Medical Science, University of South Australia, Adelaide, SA, Australia

DOI:

https://doi.org/10.51173/ijmhs.v1i1.17

Keywords:

Quinolones , Chemical Structure , Immunomodulatory Effect , Intracellular Penetration

Abstract

Background: Previous studies have shown that several antibiotics have significant side effects in addition to their antibacterial ones, which are indirectly mediated by altering and controlling the mediators of the immune system. The synthetic antibiotics known as fluoroquinolones (FQs) were discovered that fluoroquinolones (FQs) have an impact on humoral and cellular immunity. Typically, FQs only have their moderating effects when combined with another stimulant.   

Conclusion: This review presented the suitability of fluoroquinolones for potential use in medicine in order to manage several infectious diseases. These FQs are highly effective antibiotics against the bacterial infections. They are therefore prone to misuse, which can result in patients experiencing unwanted side effects and the continued development of antibiotic resistance. Even though quinolones can be used empirically to treat patients in an outpatient setting, doctors still need to follow up with patients to make sure the course of antibiotics is completed and to confirm the success of the treatment. When culture and sensitivity data are available, patients should be switched to more focused antibiotics so that quinolones can be stopped. It is advisable for clinicians to use another antibiotic if a patient is at high risk for serious side effects. In order to discuss alternate antibiotics, confirm dosage, and find any drug-drug interactions, a pharmaceutical consultation may be beneficial. In order to prevent serious side effects from occurring when using quinolones, the patient and their healthcare providers should be informed by the pharmacist and the doctor. Physicians should exercise caution while treating life-threatening gram-positive infections with quinolone antibiotics, even if the more recent fluoroquinolones have demonstrated encouraging in vitro activity against gram-positive bacteria based on MIC data. Future quinolone efficacy is likely to be constrained by the ongoing abuse of these antibiotics in clinical care and agricultural feed, which will encourage gram-positive and gram-negative resistance. Overuse of one agent will eventually cause the class as a whole to become resistant.

References

References

Huda Minhas, OD, Michael S. Cooper, OD (2024). The OD's Guide to Systemic and Topical Antibiotics with Cheat Sheet. Eyes On Eyecare. https://eyesoneyecare.com/resources/optometrists-guide-ocular-antibiotics.

Anwar, A. I., Lu, L., Plaisance, C. J., Daniel, C. P., Flanagan, C. J., Wenger, D. M., ... & Kaye, A. D. (2024). Fluoroquinolones: Neurological Complications and Side Effects in Clinical Practice. Cureus, 16(2).‏ DOI: 10.7759/cureus.54565.

Landers, Z. D., & Mazhar, A. (2024). Fluoroquinolone-Induced Multisystem Toxicity: A Case Report. Cureus, 16(5).‏ DOI: 10.7759/cureus.61174.

Li, Y., Wang, J., Wang, C., & Chen, L. (2024). Safety analysis of quinolones use in minors—based on the FAERS database. Frontiers in Medicine, 11, 1437376.‏ https://doi.org/10.3389/fmed.2024.1437376.

Gueta, I., Yonath, H., Fluss, R., Oberman, B., Oppenheim, A., Ozeri, D., ... & Loebstein, R. (2024). Fluoroquinolones and the risk for incidental seizures: a comparative retrospective study. Journal of Antimicrobial Chemotherapy, 79(10), 2554-2560.‏ https://doi.org/10.1093/jac/dkae255.

Papadakis, M. A. (2024). Current medical diagnosis & treatment 2024. http://thuvienso.thanglong.edu.vn//handle/TLU/10775.

Rusu, A., Munteanu, A. C., Arbănași, E. M., & Uivarosi, V. (2023). Overview of side-effects of antibacterial fluoroquinolones: new drugs versus old drugs, a step forward in the safety profile?. Pharmaceutics, 15(3), 804. https://doi.org/10.3390/pharmaceutics15030804.

Al Masud, M. A., Shin, W. S., Septian, A., Samaraweera, H., Khan, I. J., Mohamed, M. M., ... & Rahman, S. (2024). Exploring the environmental pathways and challenges of fluoroquinolone antibiotics: A state-of-the-art review. Science of The Total Environment, 171944.‏ https://doi.org/10.1016/j.scitotenv.2024.171944.

Serwacki, P., Gajda, M., Świątek-Kwapniewska, W., Wałaszek, M., Nowak, K., & Wójkowska-Mach, J. (2024). Re-evaluating the suitability of using fluoroquinolones in the treatment of infections in the context of FQ consumption and correlating changes to microorganism resistance levels in EU/EEA countries between 2016 and 2021. Naunyn-schmiedeberg's Archives of Pharmacology, 397(2), 795-805.‏ https://doi.org/10.1007/s00210-023-02622-2.

Al Masud, M. A., Shin, W. S., Septian, A., Samaraweera, H., Khan, I. J., Mohamed, M. M., ... & Rahman, S. (2024). Exploring the environmental pathways and challenges of fluoroquinolone antibiotics: A state-of-the-art review. Science of The Total Environment, 171944.‏ https://doi.org/10.1016/j.scitotenv.2024.171944.

Bausch, K., & Bonkat, G. (2022). Fluoroquinolone antibiotics–what we shouldn’t forget two years after the restriction by the European Commission. Swiss Medical Weekly, 152(0304), w30126-w30126.‏ https://doi.org/10.4414/SMW.2022.w30126.

Kloskowski, T., Frąckowiak, S., Adamowicz, J., Szeliski, K., Rasmus, M., Drewa, T., & Pokrywczyńska, M. (2022). Quinolones as a Potential Drug in Genitourinary Cancer Treatment—A Literature Review. Frontiers in oncology, 12, 890337.‏ https://doi.org/10.3389/fonc.2022.890337.

Millanao, A. R., Mora, A. Y., Villagra, N. A., Bucarey, S. A., & Hidalgo, A. A. (2021). Biological effects of quinolones: a family of broad-spectrum antimicrobial agents. Molecules, 26(23), 7153.‏ https://doi.org/10.3390/molecules26237153.

Wassenaar, T. M. (2005). Use of antimicrobial agents in veterinary medicine and implications for human health. Critical reviews in microbiology, 31(3), 155-169. https://doi.org/10.1080/10408410591005110.

Yudhawati, R., & Wicaksono, N. F. (2024). Immunomodulatory Effects of Fluoroquinolones in Community-Acquired Pneumonia-Associated Acute Respiratory Distress Syndrome. Biomedicines, 12(4), 761. 10.3390/biomedicines12040761.

Blondeau, J. M. (2000). A review of clinical trials with fluoroquinolones with an emphasis on new agents. Expert Opinion on Investigational Drugs, 9(2), 383-413.‏ https://doi.org/10.1517/13543784.9.2.383.

Ball, P., Fernald, A., & Tillotson, G. (1998). Therapeutic advances of new fluoroquinolones. Expert opinion on investigational drugs, 7(5), 761-783.‏ https://doi.org/10.1517/13543784.7.5.761.

Gold, H. S., & Moellering Jr, R. C. (1996). Antimicrobial-drug resistance. New England journal of medicine, 335(19), 1445-1453.‏ DOI: 10.1056/NEJM199611073351907.

Owens Jr, R. C., & Ambrose, P. G. (2000). Clinical use of the fluoroquinolones. Medical Clinics of North America, 84(6), 1447-1469.‏. https://doi.org/10.1016/S0025-7125(05)70297-2.

‏Ball, P. (2000). Quinolone generations: natural history or natural selection?. Journal of Antimicrobial Chemotherapy, 46(suppl_3), 17-24.‏ https://doi.org/10.1093/oxfordjournals.jac.a020889.

Emmerson, A. M., & Jones, A. M. (2003). The quinolones: decades of development and use. Journal of Antimicrobial Chemotherapy, 51(suppl_1), 13-20.‏ https://doi.org/10.1093/jac/dkg208.

Nelson, J. M., Chiller, T. M., Powers, J. H., & Angulo, F. J. (2007). Fluoroquinolone-resistant Campylobacter species and the withdrawal of fluoroquinolones from use in poultry: a public health success story. Clinical Infectious Diseases, 44(7), 977-980. https://doi.org/10.1086/512369.

Reddy, A. K., Garg, P., Alam, M. R., Gopinathan, U., Sharma, S., & Krishnaiah, S. (2010). Comparison of in vitro susceptibilities of Gram-positive cocci isolated from ocular infections against the second and fourth generation quinolones at a tertiary eye care centre in South India. Eye, 24(1), 170-174.‏ https://doi.org/10.1038/eye.2009.29.

Mather, R., Karenchak, L. M., Romanowski, E. G., & Kowalski, R. P. (2002). Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. American journal of ophthalmology, 133(4), 463-466. https://doi.org/10.1016/S0002-9394(02)01334-X.‏

Callegan, M. C., Ramirez, R., Kane, S. T., Cochran, D. C., & Jensen, H. (2003). Antibacterial activity of the fourth-generation fluoroquinolones gatifloxacin and moxifloxacin against ocular pathogens. Advances in therapy, 20, 246-252.‏ https://doi.org/10.1007/BF02849853.

Haas, W., Pillar, C. M., Zurenko, G. E., Lee, J. C., Brunner, L. S., & Morris, T. W. (2009). Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrobial agents and chemotherapy, 53(8), 3552-3560.‏ https://doi.org/10.1128/aac.00418-09.

Milatovic, D., Schmitz, F. J., Brisse, S., Verhoef, J., & Fluit, A. C. (2000). In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates. Antimicrobial agents and chemotherapy, 44(4), 1102-1107.‏ https://doi.org/10.1128/aac.44.4.1102-1107.2000.

Blondeau, J. M. (2004). Fluoroquinolones: mechanism of action, classification, and development of resistance. Survey of ophthalmology, 49(2), S73-S78.‏. https://doi.org/10.1016/j.survophthal.2004.01.005.

Poole, K. (2005). Efflux-mediated antimicrobial resistance. Journal of Antimicrobial Chemotherapy, 56(1), 20-51.‏ https://doi.org/10.1093/jac/dki171.

Cambau, E., Matrat, S., Pan, X. S., Roth Dit Bettoni, R., Corbel, C., Aubry, A., ... & Fisher, L. M. (2009). Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. Journal of Antimicrobial Chemotherapy, 63(3), 443-450.‏. https://doi.org/10.1093/jac/dkn528.

Sappal, R., Chaudhary, R. K., Sandhu, H. S., & Sidhu, P. K. (2009). Pharmacokinetics, urinary excretion and plasma protein binding of danofloxacin following intravenous administration in buffalo calves (Bubalus bubalis). Veterinary research communications, 33, 659-667.‏. https://doi.org/10.1007/s11259-009-9215-6.

Chide, O. E., & Orisakwe, O. E. (2007). Structural development, haematological immunological and pharmacological effects of quinolones. Recent Patents on Anti-Infective Drug Discovery, 2(2), 157-168.‏ DOI: https://doi.org/10.2174/157489107780832668.

Tuccori, M., Guidi, B., Carulli, G., Blandizzi, C., Tacca, M. D., & Di Paolo, M. (2008). Severe thrombocytopenia and haemolytic anaemia associated with ciprofloxacin: a case report with fatal outcome. Platelets, 19(5), 384-387. https://doi.org/10.1080/09537100801993040.

A diagram presenting chemical structure-side effect relationships for the quinolone antibiotics

Downloads

Published

2024-11-10

How to Cite

Mahmood, A., Liu, X., Grice, J., Medley, G., & Roberts, M. (2024). The Efficacy of Quinolones and Fluoroquinolones in the Medicine: a review study. Iraqi Journal of Medical and Health Sciences, 1(1), 27–35. https://doi.org/10.51173/ijmhs.v1i1.17

Issue

Vol. 1 No. 1 (2024): November - 2024

Section

Medicine ( Miscellaneous)

License

Copyright (c) 2024 Adnan Mahmood, Xin Liu, Jeffrey Grice, Gregory Medley, Michael Roberts

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.